Baxter Advate approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Baxter's clotting factor Advate (recombinant antihemophilic factor plasma/albumin-free [rAHF-PFM]) clears FDA July 25 for treatment of hemophilia A. Advate is the only factor VIII manufactured without human or animal plasma proteins, "thereby eliminating the risk of infections caused by viruses that may be carried in these proteins." The firm is touting the product's purity and "greater convenience based on its higher potency and lower infusion volume" compared to its previous rAHF product,Recombinate. Advate will be priced slightly higher than Recombinate when it begins shipping in the next few weeks, Baxter says
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.